These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37876734)

  • 41. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Affordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioning.
    Sagaon-Teyssier L; Singh S; Dongmo-Nguimfack B; Moatti JP
    J Int AIDS Soc; 2016; 19(1):20619. PubMed ID: 27765142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of generic drug prices in seven European countries: a methodological analysis.
    Wouters OJ; Kanavos PG
    BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is greater generic competition also linked to lower drug prices in South Korea?
    Son KB
    Health Econ Rev; 2020 Sep; 10(1):30. PubMed ID: 32930889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
    Godman B; Shrank W; Wettermark B; Andersen M; Bishop I; Burkhardt T; Garuolienè K; Kalaba M; Laius O; Joppi R; Sermet C; Schwabe U; Teixeira I; Tulunay FC; Wendykowska K; Zara C; Gustafsson LL
    Pharmaceuticals (Basel); 2010 Aug; 3(8):2470-2494. PubMed ID: 27713363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010.
    Kaplan WA; Ritz LS; Vitello M; Wirtz VJ
    Health Policy; 2012 Aug; 106(3):211-24. PubMed ID: 22694970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of French generic medicines retail market: why the use of generic medicines is limited.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):795-803. PubMed ID: 25095903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.
    Lessing C; Ashton T; Davis PB
    J Prim Health Care; 2015 Jun; 7(2):94-101. PubMed ID: 26125054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia.
    Tesar T; Golias P; Masarykova L; Kawalec P; Inotai A
    Front Pharmacol; 2021; 12():795002. PubMed ID: 34966285
    [No Abstract]   [Full Text] [Related]  

  • 50. Trends in generic prescribing and dispensing in Europe.
    Simoens S
    Expert Rev Clin Pharmacol; 2008 Jul; 1(4):497-503. PubMed ID: 24410552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biosimilars: How Can Payers Get Long-Term Savings?
    Mestre-Ferrandiz J; Towse A; Berdud M
    Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is the price right? Paying for value today to get more value tomorrow.
    Ramagopalan SV; Diaz J; Mitchell G; Garrison LP; Kolchinsky P
    BMC Med; 2024 Jan; 22(1):45. PubMed ID: 38287326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.
    Gaayeb L; Das A; James I; Murthy R; Nobre S; Burrone E; Morin S
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26092. PubMed ID: 37439078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Availability, pricing and affordability of selected medicines for noncommunicable diseases.
    Heidari E; Varmaghani M; Abdollahiasl A
    East Mediterr Health J; 2019 Oct; 25(7):473-480. PubMed ID: 31612979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Controlling medicine prices in Sudan: the challenge of the recently established medicines regulatory authority.
    Ali GK; Yahia Y
    East Mediterr Health J; 2012 Aug; 18(8):811-20. PubMed ID: 23057369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative price analysis of biological medicines: disparities generated by different pricing policies.
    Pontes MA; Ribeiro AA; Albuquerque FC; Leite Cotenzini SN
    Front Pharmacol; 2023; 14():1256542. PubMed ID: 38273835
    [No Abstract]   [Full Text] [Related]  

  • 58. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overview of external reference pricing systems in Europe.
    Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
    Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R
    Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.